Ardelyx, Inc. (NASDAQ:ARDX – Get Free Report) has been given an average rating of “Moderate Buy” by the twelve brokerages that are currently covering the company, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a sell rating, nine have issued a buy rating and one has assigned a strong buy rating to the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $13.90.
Several equities analysts have recently issued reports on the company. LADENBURG THALM/SH SH initiated coverage on Ardelyx in a research report on Tuesday, June 16th. They set a “buy” rating and a $16.00 price target on the stock. Zacks Research lowered Ardelyx from a “hold” rating to a “strong sell” rating in a report on Wednesday, July 22nd. TD Cowen decreased their target price on Ardelyx from $13.00 to $10.00 and set a “buy” rating for the company in a research note on Friday, August 7th. BTIG Research lowered their target price on Ardelyx from $17.00 to $14.00 and set a “buy” rating on the stock in a report on Friday, August 7th. Finally, Citigroup dropped their price target on shares of Ardelyx from $14.00 to $11.00 and set a “buy” rating on the stock in a research report on Monday, August 10th.
Check Out Our Latest Analysis on ARDX
Ardelyx Trading Down 0.6%
Ardelyx (NASDAQ:ARDX – Get Free Report) last announced its earnings results on Thursday, August 6th. The biopharmaceutical company reported ($0.07) EPS for the quarter, missing the consensus estimate of ($0.05) by ($0.02). The firm had revenue of $120.88 million for the quarter, compared to the consensus estimate of $121.03 million. Ardelyx had a negative return on equity of 36.00% and a negative net margin of 12.35%.Ardelyx’s revenue for the quarter was up 34.3% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.08) EPS. As a group, equities research analysts expect that Ardelyx will post -0.2 EPS for the current fiscal year.
Insider Buying and Selling
In related news, insider John E. Bishop sold 19,750 shares of the stock in a transaction that occurred on Friday, August 21st. The shares were sold at an average price of $3.86, for a total transaction of $76,235.00. Following the completion of the sale, the insider directly owned 317,095 shares of the company’s stock, valued at $1,223,986.70. This represents a 5.86% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider James Brady sold 15,136 shares of the firm’s stock in a transaction that occurred on Friday, August 21st. The stock was sold at an average price of $3.86, for a total transaction of $58,424.96. Following the sale, the insider owned 245,930 shares of the company’s stock, valued at $949,289.80. The trade was a 5.80% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 126,059 shares of company stock worth $486,588. 5.30% of the stock is owned by insiders.
Institutional Inflows and Outflows
Several institutional investors have recently modified their holdings of ARDX. Krensavage Asset Management LLC grew its holdings in shares of Ardelyx by 6.9% in the 2nd quarter. Krensavage Asset Management LLC now owns 534,523 shares of the biopharmaceutical company’s stock worth $2,726,000 after acquiring an additional 34,523 shares during the last quarter. NewEdge Advisors LLC raised its position in shares of Ardelyx by 30.0% during the second quarter. NewEdge Advisors LLC now owns 23,724 shares of the biopharmaceutical company’s stock worth $121,000 after purchasing an additional 5,476 shares during the period. Squarepoint Ops LLC lifted its holdings in shares of Ardelyx by 2.6% during the second quarter. Squarepoint Ops LLC now owns 715,262 shares of the biopharmaceutical company’s stock valued at $3,648,000 after purchasing an additional 17,978 shares during the last quarter. Headlands Technologies LLC lifted its holdings in shares of Ardelyx by 8.2% during the second quarter. Headlands Technologies LLC now owns 240,796 shares of the biopharmaceutical company’s stock valued at $1,228,000 after purchasing an additional 18,264 shares during the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in shares of Ardelyx by 10.4% in the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 486,412 shares of the biopharmaceutical company’s stock valued at $2,481,000 after purchasing an additional 45,738 shares during the period. Institutional investors own 58.92% of the company’s stock.
Trending Headlines about Ardelyx
Here are the key news stories impacting Ardelyx this week:
- Negative Sentiment: Multiple law firms publicized a securities class action against Ardelyx on behalf of investors who purchased shares between January 13, 2025, and August 6, 2026. The lawsuits allege that the company misrepresented payer utilization-management restrictions and prescription “pull-through,” which allegedly limited patient access and slowed new-patient starts for IBSRELA. ARDX Shareholder Alert: Ardelyx, Inc. Securities Class Action Lawsuit
- Negative Sentiment: The complaints point to a gap between Ardelyx’s previously stated potential for approximately $1.75 billion in combined peak sales for IBSRELA and XPHOZAH and subsequent developments, including reduced 2026 guidance and withdrawal of its long-term XPHOZAH sales target. These allegations raise questions about the reliability of prior growth expectations, although they have not been proven in court. Promise vs. Reality: Ardelyx Shareholder Alert
- Neutral Sentiment: The notices largely repeat the same litigation information rather than announcing a new operating development. Investors who seek to serve as lead plaintiff generally must act by November 16, 2026. The legal proceedings could create reputational, financial, and management-distraction risks, but their ultimate outcome remains uncertain. Rosen Ardelyx Securities Class Action Deadline
Ardelyx Company Profile
Ardelyx, Inc is a biopharmaceutical company focused on developing and commercializing therapies for gastrointestinal and cardiorenal conditions. The company’s lead product candidates and marketed medicines are designed to address disorders involving the regulation of phosphate and other substances in the digestive system.
Ardelyx markets XPHOZAH (tenapanor) in the United States for reducing serum phosphorus in adults with chronic kidney disease on dialysis. Tenapanor works locally in the gastrointestinal tract by inhibiting the sodium/hydrogen exchanger 3, thereby reducing intestinal phosphate absorption.
Featured Articles
- Five stocks we like better than Ardelyx
- CarMax Just Gave Investors a Better Reason to Believe in the Turnaround
- CoreWeave Comes With Risks: Analysts Split on What Matters Most
- Bottlenecking the Future: TSMC Prices Out the Competition
- Fervo Energy Hits Geothermal Milestone: Will It Matter For The Stock?
Receive News & Ratings for Ardelyx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ardelyx and related companies with MarketBeat.com's FREE daily email newsletter.
